MoonLake Immunotherapeutics (MLTX) News
Follow MoonLake Immunotherapeutics (MLTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 22 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
MoonLake Immunotherapeutics Shares Rise 0.8%
MoonLake Immunotherapeutics shares were up 0.8% following its Q3 financial results.
EQUITY | Nov 04, 2026, 02:54 PM UTC
M
MoonLake Immunotherapeutics Reports Quarterly Results
MoonLake Immunotherapeutics reported results for the quarter ended September 30.
EQUITY | Nov 04, 2026, 01:42 PM UTC
M
MoonLake Immunotherapeutics Reports Third-Quarter Net Loss of $79.5M
The clinical-stage company reported a net loss attributable to controlling shareholders of $79.5 million, compared with $69.7 million a year earlier, and no product sales revenue. Basic and diluted loss per share narrowe
EQUITY | Nov 04, 2026, 12:22 PM UTC
M
MoonLake Q3 Net Loss Widens as R&D Costs Rise
EQUITY | Nov 04, 2026, 12:18 PM UTC
M
MoonLake Reports Third-Quarter 2026 Financial Results and Business Update
MoonLake said it submitted a Biologics License Application for sonelokimab to the U.S. Food and Drug Administration.
EQUITY | Nov 04, 2026, 12:15 PM UTC
M
Multiple Companies Price Offerings
Several companies announce pricing of various offerings
EQUITY | Aug 11, 2026, 09:30 AM UTC
L
MoonLake Immunotherapeutics' CFO Sells 39K Shares
2026-07-03 10:34:01 ET On June 22, Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics
EQUITY | Jul 03, 2026, 02:34 PM UTC
L
Leerink Partners Maintains Outperform on MoonLake, Raises Price Target to $29
Leerink Partners analyst Thomas Smith maintains MoonLake (NASDAQ: MLTX ) with a Outperform and raises the price target from $24 to $29.
EQUITY | Jul 01, 2026, 01:23 PM UTC
H
HTZ: -21% on Notes Offering
Hertz Global Holdings is down 21% premarket on a proposed offering of $300 million of exchangeable senior first-lien secured PIK notes and $100 million of common stock
EQUITY | Jun 24, 2026, 01:13 PM UTC
M
MLTX Prices $200M Offering
MoonLake Immunotherapeutics announces pricing of upsized $200 million public offering
EQUITY | Jun 24, 2026, 09:14 AM UTC
M
MLTX Prices $200M Offering
MoonLake Immunotherapeutics prices upsized $200M public offering of 9M Class A ordinary shares at $20.00 per share
EQUITY | Jun 24, 2026, 05:51 AM UTC
L
CDNL: Proposes Public Offering
CDNL proposes public offering of common stock
EQUITY | Jun 23, 2026, 09:24 AM UTC
M
CDNL: Proposes Public Offering
CDNL proposes public offering of common stock, among other equity offerings from various companies
EQUITY | Jun 22, 2026, 09:10 PM UTC
M
MLTX: Announces $150M Share Offering
MoonLake Immunotherapeutics announces proposed public offering of $150M of its Class A ordinary shares
EQUITY | Jun 22, 2026, 08:06 PM UTC
M
MLTX Proposes Public Offering
MoonLake Immunotherapeutics announces proposed public offering
EQUITY | Jun 22, 2026, 08:01 PM UTC
H
DFTX +65% on Phase 3 Results
DFTX shares rise 65% on positive topline results from Phase 3 Emerge Study of DT120
EQUITY | Jun 22, 2026, 01:17 PM UTC
H
APGE +45% on Acquisition
AbbVie to acquire Apogee Therapeutics, sending APGE stock up 45% premarket
EQUITY | Jun 22, 2026, 12:21 PM UTC
M
MLTX Reports Sonelokimab Results
MoonLake announces week 52 results of sonelokimab from its phase 3 VELA program in hidradenitis suppurativa
EARNINGS | Jun 22, 2026, 09:26 AM UTC
H
SAGT Surges 76%
Sagtec Global shares rise 75.6% in pre-market trading after issuing financial year 2026 guidance projecting 35% revenue growth
EQUITY | Jun 22, 2026, 09:23 AM UTC
H
MLTX: Reports Phase 3 VELA Results
MoonLake announces Phase 3 VELA program week 52 results showing 67.2% of sonelokimab-treated patients achieving HiSCR75 in moderate-to-severe hidradenitis suppurativa
EARNINGS | Jun 22, 2026, 08:05 AM UTC